FDA Approves Pegfilgrastim-apgf) Biosimilar to Pegfilgrastim

On June 11, 2020, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Nyvepria™ (pegfilgrastim-apgf), a biosimilar to Neulasta® (pegilgrastim). Nyvepria is indicated to decrease incidence of infection as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Read corporate press release.

Posted 6/12/2020